Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 15,000 shares of the stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $17.67, for a total value of $265,050.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Friday, December 1st, Corp /De/ Celgene sold 87,991 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.10, for a total value of $1,680,628.10.
  • On Wednesday, November 29th, Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.25, for a total value of $82,062.75.
  • On Monday, November 27th, Corp /De/ Celgene sold 27,990 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.75, for a total value of $552,802.50.
  • On Friday, November 24th, Corp /De/ Celgene sold 26,010 shares of Crispr Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $520,200.00.
  • On Wednesday, November 22nd, Corp /De/ Celgene sold 256,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.76, for a total value of $5,058,560.00.
  • On Monday, November 20th, Corp /De/ Celgene sold 158,718 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.02, for a total value of $3,018,816.36.
  • On Friday, November 17th, Corp /De/ Celgene sold 51,282 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.44, for a total value of $945,640.08.
  • On Monday, November 13th, Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.76, for a total value of $1,156,051.68.
  • On Friday, November 10th, Corp /De/ Celgene sold 10,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $17.28, for a total value of $172,800.00.
  • On Wednesday, November 8th, Corp /De/ Celgene sold 16,875 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.06, for a total value of $304,762.50.

Shares of Crispr Therapeutics AG (NASDAQ CRSP) traded up $0.01 during midday trading on Thursday, reaching $18.53. The company’s stock had a trading volume of 197,500 shares, compared to its average volume of 142,711. Crispr Therapeutics AG has a 52-week low of $11.63 and a 52-week high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). The firm had revenue of $2.39 million during the quarter, compared to analyst estimates of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The business’s quarterly revenue was up 54.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($2.77) earnings per share. equities research analysts predict that Crispr Therapeutics AG will post -2.46 earnings per share for the current year.

A number of research firms recently weighed in on CRSP. SunTrust Banks restated a “hold” rating and issued a $16.00 price target on shares of Crispr Therapeutics in a research note on Friday, November 10th. Cann reaffirmed a “hold” rating on shares of Crispr Therapeutics in a report on Thursday, November 9th. Barclays reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Crispr Therapeutics in a report on Friday, September 8th. BidaskClub lowered Crispr Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, December 2nd. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Crispr Therapeutics in a report on Monday, August 14th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Crispr Therapeutics has a consensus rating of “Hold” and an average price target of $22.38.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRSP. Wells Fargo & Company MN grew its holdings in shares of Crispr Therapeutics by 459.7% during the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after purchasing an additional 6,560 shares in the last quarter. Capital Investment Advisory Services LLC acquired a new stake in shares of Crispr Therapeutics during the 3rd quarter worth $193,000. Ark Investment Management LLC acquired a new stake in shares of Crispr Therapeutics during the 2nd quarter worth $206,000. Moloney Securities Asset Management LLC acquired a new stake in shares of Crispr Therapeutics during the 3rd quarter worth $235,000. Finally, Vanguard Group Inc. acquired a new stake in shares of Crispr Therapeutics during the 2nd quarter worth $273,000. 24.55% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Crispr Therapeutics AG (CRSP) Major Shareholder Sells 15,000 Shares of Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/07/insider-selling-crispr-therapeutics-ag-crsp-major-shareholder-sells-15000-shares-of-stock.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.